Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8116 to 8130 of 8906 results

  1. The clinical and cost effectiveness of proton pump inhibitors for the treatment of dyspepsia (TA7)

    This guidance has been replaced by NICE guideline CG17. [Replaced by NICE guideline CG184]

    Withdrawn guidance

  2. Selinexor with low-dose dexamethasone for treating refractory multiple myeloma (terminated appraisal) (TA700)

    This guidance has been updated and replaced by NICE technology appraisal guidance 970 and NICE technology appraisal guidance 974.  

    Withdrawn guidance

  3. Rituximab for aggressive non-Hodgkin's lymphoma (TA65)

    After consultation the guidance has been withdrawn because it is no longer relevant to clinical practice. Rituximab is now routinely used outside its licensed indication. See NICE’s guideline on non-Hodgkin’s lymphoma.

    Withdrawn guidance

  4. Alpelisib with fulvestrant for treating hormone-receptor positive, HER2-negative, PIK3CA-positive advanced breast cancer (terminated appraisal) (TA652)

    This guidance has been updated and replaced by NICE technology appraisal guidance 816.

    Withdrawn guidance

  5. The clinical effectiveness and cost effectiveness of new drugs for bipolar disorder (TA66)

    This guidance has been updated and replaced NICE guideline CG38.

    Withdrawn guidance

  6. Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia (TA663)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1119.

    Withdrawn guidance

  7. Trifluridine–tipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more therapies (TA669)

    This guidance has been updated and replaced by NICE technology appraisal guidance 852.

    Withdrawn guidance

  8. The clinical effectiveness and cost effectiveness of amantadine and oseltamivir for the prophylaxis of influenza (TA67)

    This guidance has been updated and replaced NICE technology appraisal guidance 158.

    Withdrawn guidance

  9. Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA711)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA815.

    Withdrawn guidance

  10. FebriDx for C-reactive protein and Myxovirus resistance protein A testing in primary care (MIB114)

    This advice has been updated and replaced by NICE medtech innovation briefing 224.

    Withdrawn advice

  11. Mepilex Border dressings for preventing pressure ulcers (MIB124)

    This advice has been updated and replaced by NICE medical technologies guidance 40.

    Withdrawn advice

  12. Promonitor for monitoring response to biologics in rheumatoid arthritis (MIB126)

    This advice has been replaced by NICE HealthTech guidance 521.

    Withdrawn advice

  13. Health app: Sleepio for adults with poor sleep (MIB129)

    This advice has been updated and replaced by NICE healthtech guidance 624.

    Withdrawn advice

  14. Health app: ChatHealth communication platform in school nursing services (MIB130)

    The health app briefing on ChatHealth communication platform in school nursing services has been withdrawn.

    Withdrawn advice

  15. Health app: GDm-Health for people with gestational diabetes (MIB131)

    This health app briefing on GDm-Health for people with gestational diabetes has been withdrawn.

    Withdrawn advice